Transfer of ownership of Noripurum (oral and injectable), Noripurum Fólico, and Ferinject products to Blanver
On April 4th, 7th and 11th, 2022 it was published in the Brazilian Official Gazette the approval of the transfer of ownership of the products FERINJECT (ferric carboxymaltose), NORIPURUM ORAL family (ferric polymaltose), NORIPURUM FÓLICO (folic acid + ferric polymaltose), and NORIPURUM EV (ferric hydroxide saccharate) from Takeda to Blanver Farmoquímica y Farmacéutica, who became the holder of the above Registry in Brazil..
Blanver informs that by the RDC no. 102/2016, art. 47, there is a transitional period for the adequacy of the companies for the consumer service, which is 90 days.
In this regard, we request that contacts with Takeda regarding the products concerned are maintained through the following channels (from Monday to Friday, from 8 a.m. to 6 p.m., except holidays):
Phone: 0800 771 0345, Email: firstname.lastname@example.org
The batches currently available on the market, manufactured and packaged with the information provided by the former holder of the Registry (Takeda), can be normally marketed in the Brazilian territory throughout the validity period of the respective product.
We appreciate your contact and we are at your disposal.
BLANVER PHARMACO-CHEMICALS AND PHAMACEUTICAL S.A.
Rua Mario Augusto Pereira, 100 – Taboão da Serra / SP CP: 06767-330 – Phone: 55 (11) 4138-8202